Golgi apparatus in Alzheimer’s disease

doi:10.15406/jnsk.2015.02.00056

Journal of

eISSN: 2373-6410

Neurology & Stroke

Editorial Volume 2 Issue 3

Golgi apparatus in Alzheimer’s disease

Stavros J Baloyannis

Verify Captcha

Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.

Research Institute for Alzheimer’s disease, Aristotelian University, Greece

Correspondence: Stavros J Baloyannis, MD, PhD, Professor Emeritus, Aristotelia Univesity, Angelaki 5, Thessaloniki 54621, Greece, Tel 302310270434, Fax +302310434;

Received: June 17, 2014 | Published: June 19, 2015

Citation: Baloyannis SJ (2015) Golgi apparatus in Alzheimer’s disease. J Neurol Stroke 2(3): 00056. DOI: 10.15406/jnsk.2015.02.00056

Download PDF

Keywords

Alzheimer’s disease, Golgi apparatus, Organelles, Electron microscopy, Morphometry, Protein trafficking, Aβ peptide, Synaptic plasticity

Abbreviations

AD, Alzheimer’s Disease; GA, Golgi Apparatus; ER, Endoplasmic Reticulum; mDNA, mitochondrial DNA; CytOX, Cytochrome c Oxidase; PS1, Preseniline1; ROS, Reactive Oxygen Species; APP, Amyloid Precursor Protein; AβPP, Amyloid-β Precursor Protein; cdk5, cyclin-dependent kinase-5; UPR, adaptive mechanisms of the Unfolded Protein Response

Editorial

Alzheimer’s disease (AD) is the most common cause of progressive and irreversiblepresenile and senile dementia of unavoidable tragicoutcome, affecting millions of humansworldwide. Even from the last decades of the 20^th century AD has become a seriousmedical challenge for aging population, inducing many ethical, legal, social, humanitarian, philosophical¹and economic problems without an obvious perspective clarityfor the near future, despite the quotidian ongoing research.²

The clinical phenomena of the disease are characterized by profound memory loss, visuo-spatial disorientation, loss of professional skills, learning inability, decline of speech fluency,gradual dysarthria,mood and behavioral disturbances and personality changes,phenomena which appear increasingly as the disease advances, complimented frequently by autonomic disorders andepileptic seizures, which progressively result in a final vegetative state, which is the common darkepilogue of the tragic life of the patients.

The neuropathological profile of AD is plotted many years prior to phenomenological appearance of the disease. It consists of (a) abnormal accumulation of Aβ peptide in the form of neuritic plaques or diffusely dispersed in the neuropile and (b) intracellular accumulations of hyper-phosphorylated tau protein in the form of neurofibrillary tangles and (c) selective neuronal loss. All these findings, which compose the main neuropathological diagnostic criteria, as key hallmarks of AD^3,4are usually observed, been dispersed in the hippocampus, the cortex of the cerebral hemispheres, and in many subcortical neuronal networks, which play a substantial role in cognition.

Electron microscopy enlarged the horizons of morphological investigation in AD and revealed dendritic, spine andmarked synaptic pathology, in association with substantialorganelle alterations, involving mostly microtubules, mitochondria,^5,6Golgi apparatus (GA)⁷and endoplasmic reticulum (ER)⁸clearly observed even in areas of the brain, where dendritic plaques and neurofibrillary tangles are infrequent.

The alterations of ER and GA result inaccumulation of misfolded proteins and neuronal loss,⁹ given that failure of the adaptive mechanisms of the unfolded protein response (UPR) may result in chronic accumulation of misfolded proteins in the ER¹⁰and impaired amyloid precursor protein (APP) processing and trafficking.¹¹

In addition Tau protein, which is accumulated in ER, Golgi complexes, and mitochondria,¹²may activate the unfolded protein response by impairing ER-associated degradation.¹³In addition all newly synthesized proteins, which are used for membranic processes, insertion or secretion, axoplasmic or dendritic flow and synaptic activity, including APP, are practically processed through the vesicles and the cisternae of Golgi complex.¹⁴

Trafficking from the cell surface and proper sorting of APP and its cleaving involved enzymes require an intact and proper functioning Golgi complex.¹⁵APP, during its trafficking,in the GAand in the endocytic pathway, generates Aβ peptide, ranging in size from 37 to 43 amino acids, by cleavage of the APP C terminal fragment.¹⁶PS1, which is a component of γ-secretase and selectively increase the secretion of the Aβ (1-42) peptide, is mainly located in the ER and the cisternae of GA,¹⁷trafficking to synapses, where it becomes component of synaptic and endothelial adherent junctions.¹⁸

The GA in the majority of the early cases of AD is fragmented and atrophic in comparison with age matched normal controls.¹⁹The number of the vacuoles and vesicles, which are associated with the Golgi complex, are reduced in most of the Purkinje and granule cells of the cerebellum, the hippocampal neurons, the acoustic and visual cortices as well as the hypothalamus.²⁰It must be emphasized that alterations of GA are also observed in the astrocytes, in endothelial cells as well as in pericytes in AD brains.²¹

The normal structure of the cisternae and vesicles of the GA in the cell body is maintained by the proteins of the Golgi matrix.²²It is reasonable that alteration of these structural proteins as an early phenomenon in AD may induce GA fragmentation and atrophy.²³The accumulation of Aβ peptide in AD, at the subclinical period, may cause fragmentation of GA by phosphorylation of GM130 or GRASP65 (Golgi reassembly and stacking protein of 65 kD)^24,25proteins by the activation of cyclin-dependent kinase-5 (cdk5), as it is well documented in transgenic mouse models.²⁶

In addition alterations of GA may influence protein glycosylation,²⁷which is among the major processing activities of the trans-Golgi network, occurring through numerous sequential steps, each of them requiring its own enzymes.²⁸

In the pathogenic chain of AD, the further fragmentation of GA induced by Aβ peptideoverproduction²⁹may reasonably affect dendritic protein trafficking, which is essentialfor dendritic remodeling and arbor stability, since microtubules are closely associated with Golgi outpost and trafficking of vesicles and proteins towards the terminal dendritic branches and spines.³⁰At the same time the Aβ peptide which is accumulated in multivesicular bodies,³¹ in association with mitochondrial dysfunction³²may inducedisruption of the synapses,³¹ a fact which is closely related with the cognitive decline in AD.

The morphological alterations of GA, which are observed even at the initial stages of AD, plead in favor of the hypothesis that impairment of trafficking in Golgi cisternae and endosomes and ER stress may be one of the crucial factors in amyloidogenesis.^27,33

It is an undoubted ascertainment that there is no effective therapeutic intervention in AD for the time being. The majority of the current therapeutic attempts have temporal effects and induce symptomatic alleviation only.

A therapeutic philosophy aiming at protection from oxidative stress, mitochondrial damage³²and hypoxic perturbations on one hand and protection of the endoplasmic reticulum⁸and Golgi complex from stress and fragmentation³⁴on the other hand, may be beneficial in the initial stages of AD, promoting restoration and remodeling of dendrites,³⁰regeneration of spines, synaptogenesis and synaptic plasticity.